Intellia Therapeutics, Inc. · NASDAQ:NTLA
Intellia Therapeutics — Investor Day (November 2026)
74 slides from Intellia Therapeutics's investor day presentation, Nov 12, 2026
Slide 1: Readying Lonvo-z for Patients with HAE
Readying Lonvo-z for Patients with HAE November 12, 2026 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation contains “forward-looking statements” of Intellia Therapeutics, Inc. (“Intellia”, “we” or “our”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements about Intelli
Slide 3: Today's Speakers and Topics
Today’s Speakers and Topics Introduction and Overview Dr. John Leonard President and Chief Executive Officer Intellia Therapeutics HAE Management in the U.S. Dr. Marc Riedl Prof. of Medicine, Clinical Director of the U.S. Hereditary Angioedema Association (HAEA) Angioedema Center University of Calif
Slide 4: Introduction & Overview
Introduction & Overview Dr. John Leonard President & Chief Executive Officer Intellia Therapeutics
Slide 5: Intellia is Leading a New Era of Medicine
Intellia is Leading a New Era of Medicine CRISPR: clustered regularly interspaced short palindromic repeats; Cas9: CRISPR-associated protein 9; ATTR-CM: ATTR amyloidosis cardiomyopathy; ATTRv-PN: hereditary ATTR amyloidosis polyneuropathy; KLKB1: kallikrein B1. Working diligently to bring the first-
Slide 6: Intellia Continues to Lead the Global In Vivo Gene Editing Revolution
Intellia Continues to Lead the Global In Vivo Gene Editing Revolution Ph3: Phase 3. Founded 2014 WORLD’S FIRST Patient dosed 2020 WORLD’S FIRST In vivo gene editing clinical data 2021 WORLD’S FIRST Ph3 clinical trial initiated 2024 WORLD’S FIRST Fully enrolled Ph3 clinical trial 2025 WORLD’S FIRST P
Slide 7: Lonvo-z BLA Under Review
Lonvo-z BLA Under Review BLA ACCEPTED BY FDA REGULATORY REVIEW Priority review granted PDUFA GOAL DATE MARCH 10, 2027 SEPTEMBER 3, 2026 FDA COMMUNICATION: “We are not currently planning to hold an advisory committee to discuss this application.” BLA: Biologics License Application; FDA: U.S. Food and
Slide 8: Lonvo-z: A One-Time Therapy Unlike Any Other
Sources: Product-specific U.S. Prescribing Information for 15 approved therapies. AAV: adeno-associated virus. Lonvo-z: A One-Time Therapy Unlike Any Other CHALLENGE Lonvo-z AAV and/or Ex Vivo Gene Therapies Screening restrictions NO YES Conditioning required NO YES Viral-vector risks NO YES Extende
Slide 9: Today's Key Takeaways
Today’s Key Takeaways DISRUPTIVE TREATMENT APPROACH ADVANCING TOWARD LAUNCH Intellia has a strong strategy and full team already in place. Proactive work is well underway in anticipation of potential approval. BENEFIT FOR ALL As a one-time treatment, lonvo-z could reduce burden and generate value fo
Slide 10: HAE Management in the U.S.
HAE Management in the U.S. Dr. Marc Riedl Prof. of Medicine, Clinical Director of the U.S. Hereditary Angioedema Association (HAEA) Angioedema Center, University of California San Diego HAELO principal investigator
Slide 11: HAE: A Rare and Debilitating Disease Often Diagnosed Early in Life
Rare, genetic and life-threatening disease Caused by a hereditary deficiency or dysfunction of the C1 inhibitor protein, leading to an imbalance in the kallikrein-kinin system and an overproduction of bradykinin Patients experience unpredictable, recurrent, painful and potentially life-threatening s
Slide 12: HCPs and Patients Have Two Primary Options to Manage HAE Today
ON-DEMAND THERAPY (ODT) ATTACK IS TREATED AS IT OCCURS PRIMARY GOAL Stop an attack in progress MECHANISMS • Target the KKS • Block the BK receptor • Replace deficient protein HCPs and Patients Have Two Primary Options to Manage HAE Today LONG-TERM PROPHYLAXIS (LTP) REPEATED ADMINISTRATION OVER A LIF
Slide 13: Shared Decision Making is Recommended in HAE Therapy
Shared Decision Making is Recommended to Ensure HAE Therapy is Optimized for Each Patient Highly variable disease Symptoms differ across patients and can shift over time Referral networks in place with HAE experts for complex cases Multiple therapy options Therapy must match medical needs, life circ
Slide 14: HAE Community is Highly Informed and Empowered
HAE Community is Highly Informed and Empowered, with HAEA Providing Tools to Make it Possible PATIENTS AND CAREGIVER RESOURCES U.S. Summit Meeting dedicated patient and caregiver education tracts Interactive Treatment Conversation Tool aids SDM Attack-Tracking Tool enables accurate reporting with HC
Slide 15: HAE is Not Solved: Burdens Persist
Common Disease Burdens Common Treatment Burdens Chronic dosing HAE is Not Solved: Burdens Persist Despite Advances in Therapies Over the Past Decade Fear of the next attack Trigger avoidance Financial toll Insurance barriers Continued attacks HAE: hereditary angioedema.
Slide 16: Patients Continue to Report Burdens of HAE
Patients Continue to Report Burdens Associated with Having HAE Even in the Era of Modern LTPs ATTACK BURDEN MENTAL HEALTH 54% rank mental health as one the most impactful disease burdens LIFE IMPACT 73% take at least two measures to avoid triggers Reported in 20251 N=100 1. Busse et al., Allergy Ast
Slide 17: Patients Concerned with Burden of Using LTPs Lifetime
Dosing burden Current LTP options necessitate chronic treatment, requiring regular dosing2-6 Administration burden LTP treatment may require daily oral administration, or immediate and recurring self- or assisted administration via IV or subcutaneous injection2-7 Once a day Every 3-4 days Most Patie
Slide 18: Insurance Barriers May Leave Patients Without Access
Insurance Barriers May Leave Patients Without Access to Medications, Which Takes a Financial and Mental Toll AREAS OF HIGH BURDEN WITH YOUR CURRENT LTP (N=89) Health Insurance Changes, Impacting Access to LTPs 80% Follow-up to Maintain Access to LTPs via Insurance 52% Medication Costs / Affordabilit
Slide 19: Lonvo-z Impressions from a Treating Physician and Principal Investigator
1 enrolled patient in lonvo-z’s HAELO Phase 3 clinical trial at the UCSD Why the patient enrolled Woman with severe Type 1 HAE who had been on multiple LTPs prior to study entry Motivations: to control her attacks, reduce treatment burden and contribute to the development of potential new treatment
Slide 20: Lonvo-z Clinical Data
Lonvo-z Clinical Data Dr. Jing L. Marantz Executive Vice President & Chief Medical Officer Intellia Therapeutics
Slide 21: Lonvo-z: Investigational One-Time HAE Treatment Inactivating KLKB1
Blood vessel after lonvo-z C1INH Factor XII Factor XIIa Kallikrein HMW kininogen Bradykinin Adapted from Zuraw BL. New England Journal of Medicine, September 2008. This presentation includes data for an investigational product not yet approved by regulatory authorities. C1INH: C1 esterase inhibitor;
Slide 22: Illustrative Lonvo-z Infusion Day
Premedication at home to mitigate IRR, oral dexamethasone 8 mg (or equivalent) DAY PRIOR DAY OF INFUSION: Illustrative Example Monitoring (up to 4 hours) 1:00–4:30 pm Patient goes home 4:30–5:00 pm Patient arrives at outpatient clinic 7:00–8:30 am Premedications to mitigate IRRs Lonvo-z is prepared
Slide 23: Phase 3 HAELO Achieved Primary and Key Secondary Endpoints
Phase 3 HAELO Trial Achieved its Primary and All Key Secondary Endpoints Data cutoff: February 10, 2026. 1. Model-based HAE attack rate using a Poisson regression model with Pearson Chi-square scaling of standard error with treatment arm and baseline attack rate (> 3 vs ≤ 3 attacks/month) as covaria
Slide 24: Our Presentations at ACAAI This Week
Our Presentations at ACAAI This Week Lonvoguran Ziclumeran Demonstrated Consistent Benefit in All Hereditary Angioedema Patient Subgroups in Ph3 HAELO Study Poster Session Integrated Analysis of Lonvoguran Ziclumeran Phase 1/2/3 Studies in Hereditary Angioedema: Efficacy Safety and Tolerability Pos
Slide 25: Our Presentations at ACAAI This Week
Our Presentations at ACAAI This Week Lonvoguran Ziclumeran Demonstrated Consistent Benefit in All Hereditary Angioedema Patient Subgroups in Ph3 HAELO Study Poster Session Integrated Analysis of Lonvoguran Ziclumeran Phase 1/2/3 Studies in Hereditary Angioedema: Efficacy Safety and Tolerability Pos
Slide 26: Improved HAE Outcomes in Patients Who Switched from LTP
Improved HAE Outcomes in HAELO Patients Who Switched from LTP HAE control before and after lonvo-z‡ Attack rate before and after lonvo-z† In the subset of the patients taking LTP at the time of study enrollment and received lonvo-z at baseline (N=35/52)*: Data as of Feb 10, 2026. *Prior use of LTP a
Slide 27: All Patient Subgroups Benefited Consistently in HAELO
All Patient Subgroups Benefited Consistently in HAELO, Regardless of Baseline Characteristics *Prior use of LTP at study entry was defined as the last dose of LTP being discontinued within 100 days of Screening-1 visit. Cohn DM, et al. New England Journal of Medicine, June 2026. CI: confidence inter
Slide 28: Our Presentations at ACAAI This Week
Our Presentations at ACAAI This Week Lonvoguran Ziclumeran Demonstrated Consistent Benefit in All Hereditary Angioedema Patient Subgroups in Ph3 HAELO Study Poster Session Integrated Analysis of Lonvoguran Ziclumeran Phase 1/2/3 Studies in Hereditary Angioedema: Efficacy Safety and Tolerability Pos
Slide 29: Robust Experience with Lonvo-z: 117 Patients
117 Patients* 93 Received one lonvo-z 50 mg dose Robust Experience with Lonvo-z: 117 Patients, Including Some with 4 Years of Follow-up in Phase 1/2 trial or Phase 3 HAELO trial 11 Received lonvo-z 25 50 mg doses in Phase 1/2 trial 2 Received one lonvo-z 25 mg dose in Phase 1/2 trial 3 Received on
Slide 30: Kallikrein Reduction Remains Deep and Durable
Kallikrein Reduction Remains Deep and Durable with up to 4 Years Follow-up; No Waning of Effect June 26, 2026 (Phase 1/2); data cutoff date: February 10, 2026 (Phase 3); July 10, 2026 (LTFU: long-term follow-up). BL: baseline; mg: milligram; SD: standard deviation.
Slide 31: Deep Attack-Rate Reduction Maintained up to 4 Years
Deep Attack-Rate Reduction and High Attack-Free Rate Maintained up to 4 Years After Lonvo-z 50 mg Lonvo-z 50 mg (n) 93 93 81 76 75 74 71 65 64 41 29 27 24 20 20 17 17 17 17 17 17 17 17 16 16 15 15 15 14 14 14 14 14 14 11 10 9 9 9 9 7 4 4 4 4 4 4 4 4 4 4 4 BL June 26, 2026 (Phase 1/2); data cutoff da
Slide 32: High Attack-Free Rate Maintained up to 4 Years
Deep Attack-Rate Reduction and High Attack-Free Rate Maintained up to 4 Years After Lonvo-z 50 mg June 26, 2026 (Phase 1/2); data cutoff date: February 10, 2026 (Phase 3); July 10, 2026 (LTFU: long-term follow-up). 31/32 patients treated with lonvo-z 50 mg remain in long-term follow-up. N shown repr
Slide 33: Favorable Safety and Tolerability Data up to 4 Years
Favorable Safety and Tolerability Data and No Long-Term Risks Observed with up to 4 Years of Follow-up Lonvo-z 50 mg (N=93) n (%) Mean (range) duration of follow-up 7.6 (0.3-46.5) months Any Treatment Emergent Adverse Event (TEAE) 82 (88) TEAE Reported in >10% of Patients Infusion related reaction 5
Slide 34: Clinical Data Summary
Clinical Data Summary HAELO DATA 81% reduction in attack rate vs. patients’ prior LTP ~3x more likely to have complete HAE control after lonvo-z than prior LTP All patient subgroups showed clinical benefit in HAELO POOLED ANALYSIS – UP TO 4 YEARS OF FOLLOW-UP Kallikrein reduction remains deep and du
Slide 35: Lonvo-z Patient Perspectives
Lonvo-z Patient Perspectives Dr. Danny Cohn Internist, Department of Vascular Medicine, Amsterdam Cardiovascular Sciences, Amsterdam University Medical Center HAELO principal investigator
Slide 36: Our Presentations at ACAAI This Week
Our Presentations at ACAAI This Week Lonvoguran Ziclumeran Demonstrated Consistent Benefit in All Hereditary Angioedema Patient Subgroups in Ph3 HAELO Study Poster Session Integrated Analysis of Lonvoguran Ziclumeran Phase 1/2/3 Studies in Hereditary Angioedema: Efficacy Safety and Tolerability Pos
Slide 37: About the Lived Experiences Study
Intent: Qualitative patient interviews were conducted to better understand patient experiences before and after receiving a one-time lonvo-z infusion Eligibility: Patients who were enrolled in the long-term follow-up study and had received at least a 50 mg dose of lonvo-z during the Phase 1/2 study
Slide 38: Patients Report Being Freed from HAE Burdens
Following Lonvo-z Dosing in Phase 1/2 Trial, Patients Generally Report Being Freed from HAE Burdens BEFORE LONVO-Z 48% of patients reported HAE as well-controlled AFTER LONVO-Z 100% of patients reported HAE as well-controlled No attacks or symptoms Fewer or less severe attacks Symptoms remaining man
Slide 39: Life Before Lonvo-z: Patients' Own Words
Life Before Lonvo-z: Patients’ Own Words A qualitative thematic analysis approach was used to analyze data collected from interviews conducted January - May 2026 among patients receiving at least 50 mg of lonvo-z in the Phase 1/2 study (N=23). HAE: hereditary angioedema. “ Description of living with
Slide 40: Life After Lonvo-z: Patients' Own Words
Life After Lonvo-z: Patients’ Own Words A qualitative thematic analysis approach was used to analyze data collected from interviews conducted January - May 2026 among patients receiving at least 50 mg of lonvo-z in the Phase 1/2 study (N=23). HAE: hereditary angioedema. “ It's really weird but I fee
Slide 41: Nearly All Respondents Described Lonvo-z as Optimal HAE Therapy
Nearly All Respondents (22 of 23) Described Lonvo-z as an Optimal HAE Therapy ONE-TIME TREATMENT FREEDOM FROM ATTACKS LIVING AS IF I DON’T HAVE HAE A qualitative thematic analysis approach was used to analyze data collected from interviews conducted January - May 2026 among patients receiving at lea
Slide 42: Lonvo-z Impressions from a Treating Physician and Principal Investigator
17 enrolled participants at Amsterdam University Medical Center 10 in lonvo-z’s Phase 1/2 trial 7 in lonvo-z’s Phase 3 trial Who enrolled and why 59% of patients were previously on LTP Many knew about lonvo-z and gene editing prior to entering prescreening Motivations: burdens associated with their
Slide 43: Readying to Revolutionize the Treatment of HAE in the U.S.
Readying to Revolutionize the Treatment of HAE in the U.S. Maria Natale Senior Vice President, Commercial Intellia Therapeutics
Slide 44: Lonvo-z Could Turn Years of Chronic Care into a One-Day Event
Lonvo-z Has the Potential to Turn Years of Chronic Care into a One-Day Event TODAY’S CHRONIC CARE CYCLE POTENTIAL FUTURE OPTION Dosing + Refills Access Reauthorizations Lifetime Burden Prevent + Treat Attacks Treatment Reassessment 1x One-Time Lonvo-z Infusion
Slide 45: Potential Broad Benefits to Patients, HCPs and Payers
Potential for Broad Benefits to Patients, HCPs and Payers Attack freedom without chronic treatment burden FOR PATIENTS Less time on administration; more on patient care FOR PHYSICIANS Reduced long-term financial burden FOR PAYERS Potential benefits depend on durability, final labeling, payer policie
Slide 46: Agenda
Agenda 1 THE MARKET 3 PATIENT PERSPECTIVE 2 HCP PERSPECTIVE 4 LAUNCH EXECUTION HCP: healthcare provider.
Slide 47: Agenda
Agenda 1 THE MARKET 3 PATIENT PERSPECTIVE 2 HCP PERSPECTIVE 4 LAUNCH EXECUTION HCP: healthcare provider.
Slide 48: About 7,500 U.S. Adults Treated for HAE; Cost of LTP
About 7,500 U.S. Adults Are Treated for HAE, and a Single Patient on LTP Can Cost the U.S. Healthcare System >$6 Million Per Decade PROJECTED CUMULATIVE COST PER PATIENT ($M) U.S. TREATED ADULTS 1. Population estimate: IQVIA LAAD+ 2018–2025. 2. Banerji A, et al. Ann Allergy Asthma Immunology, June 2
Slide 49: Agenda
Agenda 1 THE MARKET 3 PATIENT PERSPECTIVE 2 HCP PERSPECTIVE 4 LAUNCH EXECUTION HCP: healthcare provider.
Slide 50: HCPs Recognize the Burden of HAE
HCPs Recognize the Burden of HAE and Want Patients to Live as Normally as Possible NORMAL LIFE LIFELONG THERAPY 98% agree patients should live as normal a life as possible 83% worry patients will need therapy for life Source: Intellia Commissioned Market Research, October 2026 (HCP n=151). Cumulativ
Slide 51: Outsized Proportion of HCP Staff Time Allocated to HAE
An Outsized Proportion of HCP Staff Time is Allocated to HAE Source: Intellia commissioned 2026 HAE medication-management study (51 respondents, 23 U.S. facilities). HAE: hereditary angioedema; HCP: healthcare provider. DISPROPORTIONATE STAFF TIME RESOURCE STRAINS RELATED TO HAE MANAGEMENT 90% of HA
Slide 52: Strong Majority of Surveyed HCPs Would Prescribe Lonvo-z
Strong Majority of Surveyed HCPs Would Prescribe Lonvo-z; Most to ≥50% of Their Patients Source: Intellia Commissioned Market Research, October 2026 (HCP n=151). HCP: healthcare provider. PRESCRIBING OPPORTUNITY TIME TO PRESCRIPTION HCP RECEPTIVITY 65% 88% of HCPs would prescribe lonvo-z within one
Slide 53: HCPs Likely to Prescribe Lonvo-z to a Broad Range of Patients
Surveyed HCPs are Likely to Prescribe Lonvo-z to a Broad Range of Patients Source: Intellia Commissioned Market Research, October 2026 (HCP n=151). 1. % of HCPs rating 5–7 (1=not at all likely; 4=somewhat likely; 7=extremely likely). HCP: healthcare provider. HCP’s PRIORITY PATIENTS FOR LONVO-Z % OF
Slide 54: Agenda
Agenda 1 THE MARKET 3 PATIENT PERSPECTIVE 2 HCP PERSPECTIVE 4 LAUNCH EXECUTION HCP: healthcare provider.
Slide 55: Surveyed Patients Interested in Moving Beyond Chronic Therapy
Surveyed Patients Expressed Strong Interest in Moving Beyond Chronic Therapy LIFELONG THERAPY 79% very worried about needing lifelong HAE therapy Source: Intellia Commissioned Market Research, October 2026 (Patients n=156). Interest: rating 4–5 on a 5-point interest scale. Worry about lifelong thera
Slide 56: Most Surveyed Patients Would Ask About Lonvo-z
Most Surveyed Patients Would Ask About Lonvo-z, Regardless of Disease Control Source: Intellia Commissioned Market Research, October 2026 (Patients N= 156). 1. % of patients rating 5–7 (1=not at all likely; 4=somewhat likely; 7=extremely likely). HCP: healthcare provider. % OF PATIENTS LIKELY / EXTR
Slide 57: Strong Patient Interest in Lonvo-z Across All Approved LTPs
Strong Patient Interest in Lonvo-z Across All Approved LTPs Source: Intellia Commissioned Market Research, October 2026 (Patients N=156; 112 LTP users: Dawnzera n=11; Cinryze n=21; Andembry n=14; Takhzyro n=23; Orladeyo n=20; Haegarda n=22; Androgen n=1). HCP: healthcare provider; LTP: long-term pro
Slide 58: Lonvo-z the Clear Preference Leader
Lonvo-z the Clear Preference Leader Among Approved and Clinical-Stage Products Source: Intellia Commissioned Market Research, July 2026 (N=107). Pipeline products tested as blinded TPPs, based on latest publicly available data at time of study. HAE: hereditary angioedema; LTP: long-term prophylaxis.
Slide 59: HAELO Provided Evidence of Lonvo-z Interest
HAELO Provided Evidence of Lonvo-z Interest from a Contemporary Patient Population 1. HAELO Phase 3 enrolled 80 patients. LTP: long-term prophylaxis. 71% FROM LTPs; 29% FROM ODTs1 TRADE-OFFS On demand Other LTPs Lanadelumab RAPID ENROLLMENT ~50% from the U.S. Demand exceeded slots <9 months to fully
Slide 60: If Approved, Lonvo-z Could Ease Burdens for Patients, HCPs and Payers
Lonvo-z Approved Chronic LTPs Attack reduction 87% 44–89% Attack- and treatment-free 62% 0% Off prophylaxis at latest follow-up 100% 0% Dosing frequency One infusion, one time 13–365 doses per year Ongoing access burden for all One authorization, one time 1–2 reauthorizations per year If Approved, L
Slide 61: Agenda
Agenda 1 THE MARKET 3 PATIENT PERSPECTIVE 2 HCP PERSPECTIVE 4 LAUNCH EXECUTION HCP: healthcare provider.
Slide 62: Converting Interest into Treatment Upon Approval
Will Seek to Convert Interest into Treatment as Seamlessly as Possible Upon Approval 1 Patient and/or HCP learn about lonvo-z 2 HCP prescribes lonvo-z 3 Payer approves treatment 4 Treatment site and payer agree on terms 5 Infusion is scheduled 6 Patient receives 1x infusion CONVERT INTEREST CLEAR AC
Slide 63: Lessons from Prior One-Time Therapy Launches
Coverage and reimbursement took longer than expected Authorized treatment center hurdles lengthened referral-to-treatment time Prior launches struggled with late hiring and gaps in relevant experience Source: Intellia Assessment, 2024. Lessons vary by product and launch. Satisfaction with current th
Slide 64: A Team Built to Launch a One-Time Therapy in HAE
3 Specialized Dedicated experts for every step of the patient journey 1 Seasoned Average of 19 years in industry and six product launches 2 Expertise ~60% have HAE or CGT experience; 11 HAE products and 15 CGT launches 1. TEAM CGT: Cell and Gene Therapy; HAE: hereditary angioedema; PDUFA: Prescripti
Slide 65: Pre-Launch Education Ongoing with HCPs and Patients
Pre-Launch Education Ongoing with HCPs and Patients HCP ACAAI Myth Busters Symposia Full room Short format in the congress program, led by a U.S. HAELO PI HCP Intellia Virtual Lab Tour >90% of HCPs from a consortium of immunology practices attended PATIENT Gene Editing Webinar >16,000 views on the H
Slide 66: HAE Reframed Opens New Conversations About Burdens
HAE Reframed Opens New Conversations About Burdens HCP Patient 2. EDUCATION HAE: hereditary angioedema; HCP: healthcare provider. Digital · launched May 2026 95% of HAE prescribers reached Field engagement · initiated Sept 2026 1,300 priority HCPs with >2 HAE patients UPON APPROVAL: Initiating produ
Slide 67: Commercial Payers Anchor HAE with Established Pathways
PAYER MIX1 COMMERCIAL PAYERS Commercial Payers Anchor HAE with Established Pathways for One-Time Therapies Source: 1. Database Claims Analysis, June 2024. 2. Gene Therapy Coverage Assessment, March 2025 3. HHS OIG Special Advisory Bulletin: Pharmaceutical Manufacturer Copayment Coupons, September 20
Slide 68: Payer Outreach Underway and Payers Recognize Value
WHAT PAYERS VALUE ABOUT LONVO-Z OUR OUTREACH BEGAN IN EARLY 20251 Our Outreach is Well Underway and Payers Recognize Lonvo-z’s Value One-time dosing eliminates adherence issues2 Durable control is a primary value driver vs LTPs4 In vivo approach + outpatient administration3 Source: 1. Data on file.
Slide 69: ATC Network Preparation Addresses Key Barriers to Access
NETWORK REACH SITE PREPARATION PROCUREMENT FLEXIBILITY ATC Network Preparation Addresses Key Barriers to Treatment Access Illustrative network. ATC: authorized treatment center. Capabilities assessed; Interest confirmed ATC training underway Buy-and-bill Specialty pharmacy to eliminate upfront fundi
Slide 70: Expect Momentum to Build Over Year One
MONTHS 0-3 DEMAND First patient prescriptions ACCESS Exception-based access ATC NETWORK P&T and high-price committee reviews begin MONTHS 3-6 Early referrals convert First commercial policies First patients treated (first revenue generated) MONTHS 6-9 Prescriber base broadens Most commercial lives c
Slide 71: Summary of Launch Opportunity
1 HIDDEN BURDENS 79% of patients worry about lifelong therapy1 ~90% staff time unreimbursed2 10-year LTP = >$6M per patient3 2 ONE DOSE, ONE-TIME 4 years of proven durability after a single dose4 Attack freedom, no chronic burden Lower long-term cost 3 ADOPTION TAILWINDS 2.8x patient preference vs.
Slide 72: Conclusion
Conclusion Dr. John Leonard President & CEO, Intellia Therapeutics
Slide 73: Today's Key Takeaways
Today’s Key Takeaways DISRUPTIVE TREATMENT APPROACH ADVANCING TOWARD LAUNCH Intellia has a strong strategy and full team already in place. Proactive work is well underway in anticipation of potential approval. BENEFIT FOR ALL As a one-time treatment, lonvo-z could reduce burden and generate value fo
Slide 74: Q&A